Hoth Therapeutics reports 100% efficacy in Phase 2a of HT-001 for EGFRI skin toxicities

Hoth Therapeutics, Inc.

Phase 2a CLEER-001 study: 100% of patients achieved primary endpoint; 66% reported reduced pain/itching.
All patients maintained EGFR inhibitor dosage while on HT-001, preserving cancer treatment.
Preclinical data showed 56% reduction in hair loss and 58% reduction in facial lesions with preventive HT-001.
HT-001 uses 505(b)(2) pathway; IND open; NDA submission targeted for 2030.
No FDA-approved therapy exists for EGFRI-induced cutaneous toxicities; HT-001 seeks first-in-market.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.